Education
About Us
Working with TipRanks
Follow Us
NanoViricides (NNVC)
XASE:NNVC
Top Page
NanoViricides
(NYSE MKT:NNVC)
Select Model
Select Model
Rating:42Neutral
Price Target:―
NanoViricides' overall score is mainly impacted by its weak financial performance due to lack of revenue and ongoing losses. While technical analysis indicates some short-term positive momentum, the company's valuation remains a concern given its negative earnings. The absence of earnings call data and corporate events limits potential positive catalysts.
NanoViricides (NNVC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$26.96M
Dividend YieldN/A
Average Volume (3M)143.34K
Price to Earnings (P/E)―
Beta (1Y)0.60
Revenue GrowthN/A
EPS Growth32.92%
CountryUS
Employees7
SectorN/A
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.14
Shares Outstanding21,568,430
10 Day Avg. Volume199,739
30 Day Avg. Volume143,335
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.82
Price to Sales (P/S)0.00
P/FCF Ratio-2.48
Enterprise Value/Market Cap0.62
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-32.14
Enterprise Value/Ebitda-2.24
Forecast
1Y Price Target
$6.00Price Target Upside380.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
NanoViricides Business Overview & Revenue Model
Company DescriptionNanoViricides, Inc. is a development-stage company engaged in creating nanotechnology-based antiviral therapeutics. Its primary focus is on the research and development of drugs to combat viral infections by utilizing a novel platform that deploys nanomaterials to specifically target and neutralize viruses. The company operates in the biotechnology and pharmaceuticals sector, aiming to address unmet medical needs for treatments against viral diseases such as influenza, HIV, and COVID-19.
How the Company Makes MoneyNanoViricides makes money primarily through the development and commercialization of its proprietary antiviral drug candidates. As the company is primarily in the research and development phase, its current revenue streams are limited to potential grants, research collaborations, and licensing agreements with larger pharmaceutical companies. These partnerships can provide funding and resources in exchange for rights to develop or market NanoViricides' technologies. Additionally, the company may earn revenue in the future through product sales once its drugs receive regulatory approval and are launched in the market. Until then, its financial health is heavily reliant on investment funding and strategic partnerships to support its ongoing research activities.
NanoViricides Financial Statement Overview
Summary
Income Statement
20
Very Negative
Balance Sheet
50
Neutral
Cash Flow
35
Negative
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
NanoViricides Technical Analysis
Negative
1.25
Price Trends
1.43
Negative
1.44
Negative
1.42
Negative
Market Momentum
-0.05
Negative
45.99
Neutral
12.93
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NNVC, the sentiment is Negative. The current price of 1.25 is above the 20-day moving average (MA) of 1.24, below the 50-day MA of 1.43, and below the 200-day MA of 1.42, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 45.99 is Neutral, neither overbought nor oversold. The STOCH value of 12.93 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NNVC.
NanoViricides Peers Comparison
UnderperformOutperform
Sector (―)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | ― | ― | ― | ― | ― | ― | |
52 Neutral | $182.81M | -1.24 | -21.16% | ― | -92.42% | 62.37% | |
44 Neutral | $8.29M | -0.07 | ― | ― | ― | 79.31% | |
44 Neutral | $8.61M | ― | -196.60% | ― | ― | ― | |
42 Neutral | $26.96M | -2.36 | -94.03% | ― | ― | 32.92% | |
39 Underperform | $12.40M | -0.24 | ― | ― | 26.20% | -42.26% | |
36 Underperform | $20.04M | -1.55 | -57.64% | ― | ― | 46.09% |
* Sector Average
NNVC
NanoViricides
1.20
-0.31
-20.53%
CASI
CASI Pharmaceuticals
0.75
-2.32
-75.57%
ENLV
Enlivex
0.83
-0.42
-33.60%
AKTX
Akari Therapeutics
0.24
-0.74
-75.51%
MBRX
Moleculin Biotech
4.15
-40.10
-90.62%
SABS
SAB Biotherapeutics
3.84
-0.34
-8.13%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.